1. This product is suitable for the treatment of thrombocytopenia caused by chemotherapy for solid tumors. The applicable population is patients with platelet counts below 50×10^9/L and doctors consider it necessary to increase platelet treatment. 2. This product is used as an adjunctive treatment for primary immune thrombocytopenia (ITP). The applicable population is patients with platelet counts below 20×10^9/L who have not responded to glucocorticoid treatment (including initial treatment failure, or relapse after effective treatment and subsequent ineffective treatment) and have not undergone splenectomy. This product is only used for patients with thrombocytopenia and clinically increased bleeding risk and should not be used for the purpose of attempting to raise platelet counts to normal values. *Used for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents.